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Abstract 
Purpose: To demonstrate the effect of histone deacetylase-inhibitor, vorinostat, on antitumour activity 
of grape seed proanthocyanidins (GSPs) in non-small cell lung cancer (NSCLC) cells.  
Methods: Expression of thymidine phosphorlase (TP) and thymidylate synthase (TS) was measured by 
real-time PCR and western blotting. TP knockdown was performed using specific small interfering RNA. 
Antitumour activity of combination of vorinostat and GSPs was assessed according to Chou and Talay 
method and by evaluating apoptosis.  
Results: Vorinostat treatment led to a significant increase in TP expression but decrease in TS 
expression in NSCLC cells. In H157 cells, increase in the concentration of vorinostat from 0.34 to 0.4 
µM increased TP expression 3- to 6-fold. In H1299 cells, there was 7-fold reduction of TS transcript and 
30-fold increase of TP transcript at 48 h. Vorinostat, when used in combination with GSPs, resulted in a 
synergistic anti-proliferative effect and increased apoptotic cell death. However, cells with TP 
knockdown did not exhibit vorinostat- and GSPs-mediated anti-proliferative effect and apoptotic cell 
death.  
Conclusion: The combination of vorinostat and GSPs can be an effective and innovative antitumour 
therapy for the treatment of NSCLC. 
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Grape seed proanthocyanidins (GSP), mixture of 
polyphenols and flavanols exhibit anticancer 
activity with least toxicity [1-3]. The major portion 
of the extract comprises proanthocyanidins (89 
%) like catechins and/or (−)-epicatechins [1,3]. 
For determination of chemotherapeutic effects of 
GSPs an extract of grape seeds is used. It is 
reported that dietary GSPs lead to inhibition of 
lung tumor cell proliferation and the inhibition of 
angiogenic factors in human NSCLC cell 
xenografts in nude mice [4]. 
 
The anticancer agents, histone deacetylase 
inhibitors (HDAC-Is), regulate expression, 
survival and differentiation of cell cycle genes in 
tumour cells without affecting normal tissues [5-
8]. There are several HDAC-Is in preclinical 
models [6], whereas some are in advanced 
clinical development either individually or in 
combination with conventional 
chemotherapeutics or targeted agents [6,8]. It is 
reported that expression of 2–5 % of the genes is 
selectively altered by histone deacetylase 
inhibitors [6]. Vorinostat (suberoylanilide 
hydroxamic acid), the most promising HDAC-I 
exhibited promising preclinical and clinical 
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antitumour activity. It is the first HDAC-I 
approved by the Food and Drug Administration 
for the treatment of cutaneous T-cell lymphoma 
in patients with progressive, persistent or 
recurrent disease during or following two 
systemic therapies [7]. HDAC-I are also believed 
to play a vital role in thymidylate synthase (TS) 
expression [9-13]. Thymidylate synthase has a 
vital role in the synthesis of thymidilate (dTMP) 
and subsequently DNA synthesis [14]. It is 
reported that overexpression of TS induces 
resistance to 5-FU in most of the tumours [14]. 
Recently it was reported that vorinostat induces 
inhibition of TS protein in tumour cells [12]. 
 
Taking into consideration the promising 
antitumour effect of vorinostat we devised a 
study to investigate the effect of vorinostat and 
GSPs in NSCLC cells. In the present study, we 
provided evidence that by down regulating TS 
and up regulating TP mRNA and protein 
expression, vorinostat demonstrated synergistic 




Materials and cell culture 
 
Vorinostat, GSPs, tubacin and niltubacin were 
purchased from Sigma-Aldrich, USA. Human 
A549, H1299, and H157 NSCLC cell lines were 
purchased from American Type Culture 
Collections (Rockville, MD, USA). The cells were 
grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10 % heat-inactivated foetal 
bovine serum, 50UmL-1 of penicillin, 500 mgmL-1 
of streptomycin, and 4 mmoll-1 of glutamine in a 
humidified atmosphere of 95 % air and 5 % CO2 
at 37 oC. 
 
Cell survival/proliferation assay 
 
To 96-well flat bottom multiplates (BD Falcon, 
Franklin, NJ) containing 1 x 105 cells per well 
various concentrations of the drugs were added. 
After incubation for 96 h, sulforhodamine B (ICN 
Biomedicals, Irvine, CA, USA) was added to 
each well and the plates were again incubated 
for 4 h at 37 oC in 5 % CO2 incubator. A 
microplate reader (MPR-A4i; Tosoh Corporation, 
Tokyo, Japan) was used to measure absorption 
at 570 nm. All the measurements were carried 
out in triplicate. 
 
In vitro drug combination studies 
 
To determine drug combination, a range of 
equipotent doses of the two compounds were 
tested in combination. The plot of viable cells 
against concentration of the compounds tested 
was used obtain combination index (CI) using 
Chou–Talalay equation [12,15-18,]. For 
synergistic, additive or antagonistic effects the 
value of combination index corresponds to < 0.9, 
0.9 – 1.2 and 41.2, respectively. The dose 
reduction index (DRI) for each compound was 
also evaluated. 
 
Western blot analysis 
 
The cells after treatment were lysed, and using 
dye-binding method (Bio-Rad) protein 
concentration was determined. The proteins 
were resolved on 15 % SDS-PAGE and 
transferred to nitrocellulose membranes. 
Digitonin-based subcellular fractionation 
technique was used for cytosolic and 
mitochondrial fractions. Onto SDS-PAGE equal 
volumes of cytosolic and mitochondrial fractions 
were resolved and transferred to nitrocellulose 
membranes. The membranes after incubation 
with primary antibody were washed, and then 
incubated with horseradish peroxidase anti-
mouse or horseradish peroxidase anti-rabbit 
antibodies. Enhanced chemiluminescence 
system was used for visualization of 
immunoreactive bands. The primary antibodies 
used were: thymidylate synthase (TS), acetyl-H3, 
poly-(ADP-ribose)-polymerase (PARP), g-tubulin, 
platelet-derived endothelial growth factor (TP) 
and GAPDH, cleaved caspase 3 and BAX-
antibodies from Cell Signalling Technology 
(Boston, MA, USA). 
 
Analysis of apoptotic cell death by flow 
cytometry 
 
For determination of apoptosis of the human 
non-small cancer cells flow cytometry using the 
Annexin V–conjugated Alexa Fluor488 
(Alexa488) Apoptosis Detection kit was 
employed. The cells after overnight serum 
starvation were treated with different 
concentrations of vorinostat and/or 50-DFUR for 
96 h. The cells were harvested and washed in 
PBS. Then the cells were incubated with 
Alexa488 and propidium iodide in the dark. 
FACS Calibur instrument (BD Biosciences) 
equipped with the Cell Quest 3.3 software was 
used for analysis of stained cells.  
 
Reverse transcriptase-polymerase chain 
reaction (RT-PCR) 
 
Total RNA was isolated from the cells using 
Trizol (Invitrogen, Carlsbad, CA, USA) following 
the manufacturer's instructions. Total RNA was 
used for reverse transcription using DNA 
synthesis kit (Invitrogen). Primers for PCR were 
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designed and PCR amplification of cDNA was 
performed at 35 cycles in a reaction mixture 
containing 10 mM Tris–HCl (pH 8.3), 1.5 mM 
MgCl2, 50 mM KCl, 0.01 % (w/v) gelatin, 200 μM 
dNTP, TS and TP-specific primers (0.5 μM 
each), and 2.0 U of platinum Taq DNA 
polymerase (Invitrogen). For each reaction, two 
negative controls were performed consisting of 
omission of the RT step or omission of the target 
cDNA. 
 
Transient knockdown of TP using siRNA  
 
A siRNA sequences against human TP and a 
negative control Duplexes used as control for 
non-sequence-specific effects were obtained 
from (Invitrogen). Thymidine phosphorylase 
siRNA or control siRNA (33 nM) was transiently 
transfected into the cells using Lipofectamine 
2000 (Invitrogen). Briefly, siRNA: Lipofectamine 
mixture complexes were incubated for 20 min at 
room temperature and then added to cells 
growing in petri dish. After 48 h the complexes 
were replaced by complete medium and cells 




All the results are expressed as mean ± standard 
deviation (SD, n = 3). Statistical significance of 
differences was determined by two-sided 
Student’s t-test and one-way ANOVA. 
Differences were considered statistically 
significant at p ˂ 0.05. Sigma Stat software 
(Systat Software Inc., San Jose, California, USA) 




Antiproliferative effects of vorinostat and 
GSPs in NSCLC cell lines 
 
All the three (A549, H1299, and H157) NSCLC 
cell lines exhibited similar cytotoxicity to 
vorinostat. Two out of three cell lines (A549 and 
H1299) were more sensitive to GSPs compared 
to H157 cells (Table 1). 
 
Table 1: Sensitivity of NSCLC cancer cell lines to 
vorinostat and GSPs 
 
Cell lines IC50 (± SD) 
Vorinostat (mM) 
IC50 (± SD) 
GSPs (mM) 
A549 0.8 ± 0.7 0.8 ± 0.2 
H1299 0.9 ± 0.8 0.6 ± 0.1 
H157 0.5 ± 0.2 1.6 ± 0.3 
 
Effect of vorinostat on TS and TP expression 
in NSCLC cell lines 
 
The results from western blot analysis revealed a 
significant decrease in TS protein expression and 
increase in TP protein expression on treatment 
with vorinostat for 48 h in A549, H1299, and 
H157 cell lines. The observed effect was 
concentration dependent and was significant 
from the concentration of 0.34 µM vorinostat 
(Figure 1A). In H157 cells, the increase in 
concentration of vorinostat from 0.34 to 0.4 µM 
increased the TP expression from 3 to 6-fold. 
 
Vorinostat-induced down regulation of TS lead to 
clear down regulation of TS transcript in A549 
cells after 12 h with a four-fold reduction after 48 
h. Similar results were obtained for H1299 cells 
(Figure 1B). The vorinostat-induced up regulation 
of TP enhanced TP transcript in A549 cells that 
was also evident after 12 h with a 27-fold 
induction at 48 h. (Figure 1D). In H1299 cells, 
there was 7-fold reduction of TS transcript at 48 
h and 30-fold increase of TP transcript at 24 h 
(Figure 1C,E). 
 
Synergistic antitumour effects of vorinostat 
in combination with GSPs 
 
Determination of the CIs values (< 0.8) for the 
antitumour effect of vorinostat and GSPs 
combination in A549, H1299, and H157 cells 
revealed synergistic anti-proliferative effects. The 
synergistic effect was observed on treatment with 
equipotent doses of vorinostat and GSPs for 48 h 
at 50 % (CI50) or 75 % (CI75) of cell lethality 
(Table 2). There was a dose reduction in IC50 
values (DRI50) to 6-fold for both vorinostat and 
GSPs in combination compared with the 
concentrations of the two drugs alone. 
 
The results from flow cytometry showed a 
significant increase in apoptotic cell death of 
A549 and H1299 cells by combination therapy 
compared with individual treatments after 96 h 
treatment (Figure 2A,B). The doses used were 
IC30 values of vorinostat (0.34 and 0.20 µM, 
respectively) and of GSPs (3 and 5 µM, 
respectively) in A549 and H1299 cells for 96 h. 
The expression of the proapoptotic protein BAX 
and the cleavage of PARP were enhanced in 
both A549 and H1299 cells on treatment with 
vorinostat and GSPs combination (Figure 2C,D). 
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Figure 1: Effect of vorinostat on TS and TP expression in NSCLC cells. (A) TS and TP proteins expression were 
determined by western blotting on the indicated A549 and H1299 cells untreated or treated with vorinostat at 
concentration corresponding to IC50 48 h. γ-Tubulin was used as protein loading control. (B-E) TS and TP mRNA 
expression were determined by real-time PCR 
 
Table 2: Combination index (CI) and dose reduction index (DRI) values for vorinostat and GSPs combination 
treatment 
 
   aDRI at IC50 ± SD 
Cell line aCI50 ± SD  
vorinostat + GSPs 
CI75 ± SD  
vorinostat + GSPs 
Vorinostat GSPs 
A549  0.86 ± 0.27 0.69 ± 0.21 2.7 ± 0.89 5.7 ± 1.23 
H1299 0.73 ± 0.29 0.58 ± 0.18 2.1 ± 0.92 4.8 ± 1.01 
H157 0.89 ± 0.28 0.47 ± 0.13 2.96 ±1.12 4.6 ± 0.95 
aFor CI and DRI values mean ± s.d. from at least three separate experiments performed in quadruplicates were 
computed at 50 and 75 % of cell death (CI50 and CI75, respectively) according by CalcuSyn software after 96 h 
of treatment 
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Figure 2: Apoptotic effect of vorinostat in combination with GSPs on NSCLC cells. Apoptosis was evaluated by 
flow cytometry analysis after nuclear DNA staining with propidium iodide in A549 (A) and H1299 (B) cells 
untreated or treated for 72 h with vorinostat (at 0.34 and 0.20 µM, respectively) and/or GSPs (at 3 and 5 µM, 
respectively). Western blot analysis of BAX and PARP were performed on A549 (C) and H1299 (D) cells 
untreated or treated for 72 h with vorinostat (0.35 and 0.20 µM, respectively) and/or GSPs (3 and 5 µM, 




Figure 3: Knockdown of TP reduces the apoptotic effect of vorinostat in combination with GSPs on NSCLC cells. 
(A) Small interfering RNA (siRNA) for TP (siTP) significantly reduced TP mRNA expression determined by real-
time PCR both after 48 and 72 h from transfection compared with control siRNA cells (siCTR). siCTR and siTP 
NSCLC cells, 24 h after transfection were untreated or treated for 24 h with vorinostat and/or GSPs and TP (B) 
and GADD45 (C) mRNA expression were determined by real-time PCR. (D) Western blot analysis of PARP and 
acetyl histone H3 were performed on siCTR and siTP NSCLC treated as in B and C. γ-Tubulin was used as 
protein loading control 
 
Knockdown of TP reduces the apoptotic 
effect of vorinostat in combination with GSPs 
 
For investigation of the relation of TP expression 
and observed synergistic effect of 
vorinostat/GSPs on apoptosis, a specific siRNA 
was used to knockdown TP. The results showed 
a significant decrease in TP mRNA levels in the 
A549 cells transfected with siTP construct 
compared to control siRNA transfected cells 72 h 
from transfection (Figure 3A). TP knocked down 
also leads to reduction in the efficiency of 
vorinostat to enhance TP expression compared 
with control cells (Figure 3B). There was also no 
effect of vorinostat/GSPs combination on the 
GADD45, a growth-arrest and DNA-damage-
inducible gene in the cells with TP knocked down 
compared to that of control cells (Figure 3C). In 
addition, the cells with TP knocked down did not 
show enhanced cleavage of PARP and caspase 
3 on treatment with vorinostat/GSPs combination 
as observed in control cells (Figure 3D). Thus 
suggesting the importance of vorinostat induced 
TP expression up regulation for the synergistic 
anti-proliferative and apoptotic cell death induced 
by vorinostat/GSPs combination. 
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The results of the present study revealed a 
synergistic interaction between vorinostat and 
GSPs in NSCLC. We showed that the anti-
proliferative effect induced by vorinostat in 
NSCLC cells was mediated through decreased 
TS protein expression, the vital enzyme involved 
in the synthesis of thymidilate, and by increase in 
the expression of TP protein. Our results 
showing vorinostat-induced TS protein 
expression down-regulation via TS mRNA 
transcript are in agreement with earlier reports 
[9-13]. Our results for the first time revealed 
synergistic antitumour interaction between 
vorinostat and GSPs in a preclinical model. 
Earlier it was reported that promoter methylation 
can lead to inhibition of TP expression in human 
cancer cells. We also demonstrated that 
knockdown of TP by specific siRNA significantly 
inhibits the apoptotic cell death induced by 
synergistic interaction of vorinostat/GSPs 
combination. 
 
It is reported that TP-inducible chemothera-
peutics including taxanes, cisplatin or 
cyclophosphamide, in combination with 
capecitabine increased response rate, time to 
progression and survival in breast cancer 
patients in phase III studies. The phase II studies 
of gastric and NSCLC have also shown 
promising results using the above combinations 
[19-22]. The maximum concentration of 
vorinostat tolerable by human body was 
determined using two phase I pharmacokinetic 
and pharmacodynamics studies in combination 
with FOLFOX or 5-FU/LV chemotherapy 




The results indicate that vorinostat has the 
unique capability to modulate not only TS but 
also TP expression in tumour cells and, 
consequently, can synergise with GSPs. In 
addition, both vorinostat and GSPs are drugs 
that can be administered orally with consequent 
increased compliance by patients. Thus, the 
combination of vorinostat and GSPs is a 
promising chemotherapeutic strategy for the 
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